Melanoma

 

Lymph Node Dissection/Observation for Localized Melanoma (7108)
Multicenter Selective Lymphadenectomy for Melanoma Trial II: A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node [Randomization phase]

Investigator: David Byrd, MD;   Conditions: Melanoma;    Status: Recruiting;   Study ID: NCT00389571

MK-3475 Versus Chemotherapy for Advanced Melanoma (P08719/MK-3475-002)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma

Investigator: Kim Margolin, M.D.;   Conditions: Malignant Melanoma;    Status: Recruiting;   Study ID: NCT01704287

IL-2 "SELECT" for Advanced Melanoma
The High-Dose Aldesleukin (IL-2) "SELECT" Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High-Dose IL-2 Treatments in Patients With Advance Melanoma

Investigator: Kim Margolin, MD;   Conditions: Malignant Melanoma;    Status: Recruiting;   Study ID: NCT01288963

Phase I/II CD8+ NY-ESO-1 (FHCRC 2225)
Phase I/II Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cell Clones and Anti-CTLA4 for Patients With Metastatic Melanoma

Investigator: Aude Chapuis, MD;   Conditions: Melanoma (Skin);    Status: Recruiting;   Study ID: NCT00871481

IL-21/Ipilimumab Combination for Melanoma
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma

Investigator: Shailender Bhatia, M.D.;   Conditions: Melanoma;    Status: Recruiting;   Study ID: NCT01489059

Biomarker Study of Anti-PD-1 in Advanced Melanoma
An Exploratory Study of the Biologic Effects of BMS-936558 (Anti-PD-1 Monoclonal Antibody) Treatment in Subjects With Advanced Melanoma (Unresectable or Metastatic)

Investigator: Shailender Bhatia, M.D.;   Conditions: Advanced Melanoma, Metastatic Melanoma;    Status: Recruiting;   Study ID: NCT01621490

Dose-Escalation Study of MLN4924 (C15005)
A Phase I, Open-Label, Dose Escalation Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Melanoma

Investigator: Dr. Shailender Bhatia;   Conditions: Metastatic Melanoma;    Status: Closed/Not Recruiting;   Study ID: NCT01011530